PEER REVIEWED PUBLICATIONS / REFERRED JOURNAL ARTICLES

1. Zimakova IE, Salikhova RR (aka Berkovich RR), Garaev RS. The impact of tranquillizer Mebicar on the lipid metabolism on the model hypokinesia of rats. Experimental Biology and Medicine. 6:124-136, 1996. PMID: 8744131Personal contribution All experimental work, data collection and analysis, writing.

2. Rison RA and Berkovich R. Teaching NeuroImages: Hiccoughs and vomiting in neuromyelitis optica. Neurology, Vol. 75, No 17, e70, 2010. PMID: 20975046 Personal contribution: clinical observation, data collection, co-writing the manuscript.

3. Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW; Berkovich RR SENTINEL Investigators. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.

J Neurol Sci. 292(1-2):28-35, 2010. PMID: 20236661 Personal contribution: clinical investigator; reviewed, edited and approved the manuscript.

4. Berkovich R, Subhani D, Steinman L. Autoimmune Comorbid Conditions in Multiple Sclerosis. US Neurology; 7(2):132-138, 2011. Personal contribution: original idea, data collection, literature review and writing.

5. Arnason B, Berkovich R, Catania A. et al. Therapeutic mechanisms of action of adrenocorticotropic hormone (ACTH) and other melanocortin peptides for the clinical management of patients with MS. Multiple Sclerosis;19(2):130-136, 2013. PMID: 23034287 Personal contribution: clinical data collection, literature review and writing.

6. Berkovich R. Treatment of acute relapses in Multiple Sclerosis. Neurotherapeutics. Jan;10(1):97-105, 2013. PMID: 23229226 Personal contribution: clinical observations and data collection, literature review and writing.

7. Sokolov AY, Lyubashina OA, Sivachenko IB, Berkovich RR, Panteleev SS. Intravenous valproate inhibits ongoing and evoked activity of dura-sensitive thalamic neurons in rats. Eur J Pharmacol. 5;715(1-3):204-211, 2013. PMID: 23732564 Personal contribution: data review, discussion, editing and approval of the final manuscript.

8. Berkovich RR (aka Berkovich RR), Totolyan NA, Sokolov AY at al. Treatment of relapses in multiple sclerosis. Korsakoff Journal of Neurology and Psychiatry [Беркович РР, Тотолян НА, Соколов АЮ, Игнатов ЮД, Скоромец АА. Лечение обострений рассеянного склероза (обзор). Журнал неврологии и психиатрии им. С.С. Корсакова], №10:69-77, 2013. PMID: 24416811 Personal contribution: clinical observations, literature review and writing.

9. Berkovich R and Agius MA. Mechanisms of Action of ACTH in the Management of Relapsing Forms of Multiple Sclerosis. Therapeutic Advances in Neurological Disorders. 7(2):83-96, 2014. PMID: 24587825 Personal contribution: original idea and concept, literature review and writing.

10. Sokolov AY, Lyubashina OA, Berkovich RR et al. Intravenous dextromethorphan/quinidine inhibits activity of dura-sensitive spinal trigeminal neurons in rats. European Journal of Pain. 19(8):1086-1094, 2014. PMID: 23732564 Personal contribution: original idea and concept, clinical observations, literature review and writing.

11. Regina Berkovich, Daniel M. Togasaki, Steven Y. Cen and Lawrence Steinman. CD4 cell response to interval therapy with natalizumab. Annals of Clinical and Translational Neurology. 2(5): 570–574. 2015. PMID: 26000328 Personal contribution: original idea, clinical observations and data collection, literature review and writing.

12. Berkovich R and Weiner LP. Effects of dimethyl fumarate on lymphocyte subsets. Multiple Sclerosis and Related Disorders. 4:339–341, 2015. PMID: 26195053 Personal contribution: original idea, clinical observations and data collection, literature review and writing.

13. Berkovich R, Bakshi R, Amezcua L, Axtell R, Cen S, Tauhid S, Neema M and Steinman L. Adrenocorticotropic hormone versus methylprednisolone added to interferon in patients with multiple sclerosis experiencing breakthrough disease: a randomized, rater-blinded trial. Therapeutic Advances in Neurological Disorders; Oct 19, 2016 Vol. 10(1) 3-17 DOI: 10.1177/1756285616670060 Personal contribution: original idea and study design, principal investigator, literature review and writing

14. Berkovich R. Clinical and MRI outcomes after stopping or switching disease-modifying therapy in stable MS patients: a case series report. Multiple Sclerosis and Related Disorders. 2017 Oct;17:123-127. DOI: 10.1016/j.msard.2017.07.007. Epub 2017 Jul 6. Personal contribution: original idea and study design, data collection, literature review and writing.

15. Longbrake EE, Kantor D, Pawate S, Bradshaw MJ, von Geldern G, Chahin S, Cross AH, Parks BJ, Rice M, Khoury SJ, Yamout B, Zeineddine M, Russell-Giller S, Caminero-Rodriguez A, Edwards K, Lathi E, VanderKodde D, Meador W, Berkovich R, Ge L, Bacon TE, Kister I. Effectiveness of alternative dose fingolimod for multiple sclerosis. Neurol Clin Pract. 2018 Apr;8(2):102-107. doi:10.1212/CPJ.0000000000000434.

16. Berkovich RR, Sokolov AY, Togasaki DM, Yakupova AA, Cesar PH, Sahai-Srivastava S. Dextromethorphan/Quinidine in Migraine Prophylaxis: An Open-label Observational Clinical Study. Clin Neuropharmacol. 2018 Mar/Apr;41(2):64-69. doi: 10.1097/WNF.0000000000000272.PERSONAL CONTRIBUTION: ORIGINAL IDEA AND STUDY DESIGN, DATA COLLECTION, LITERATURE REVIEW AND WRITING

17. Berkovich R. Experience of Using Adrenocorticotropic Hormone in the Treatment of Patients With Acute Neuromyelitis Optica Who Failed Systemic Steroids: A Case Series.

Clin Neuropharmacol. 2019 Dec 24. doi: 10.1097/WNF.0000000000000373. PMID: 31876792 Personal contribution: original idea, clinical observations and data collection, literature review and writing.

18. Comi G, Alroughani R, Boster AL, Bass AD, Berkovich R, Fernández Ó, Kim HJ, Limmroth V, Lycke J, Macdonell RA, Sharrack B, Singer BA, Vermersch P, Wiendl H, Ziemssen T, Jacobs A, Daizadeh N, Rodriguez CE, Traboulsee A; CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators. Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies. Mult Scler. 2019 Nov 25:1352458519888610. doi: 10.1177/1352458519888610. PMID:31762387

19. Okai AF, Amezcua L, Berkovich RR, Chinea AR, Edwards KR, Steingo B, Walker A, Jacobs AK, Daizadeh N, Williams MJ; CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators. Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study).Neurol Ther. 2019 Dec;8(2):367-381. doi: 10.1007/s40120-019-00159-2. Epub 2019 Oct 25. PMID:31654272

20. Efficacy of a fourth alemtuzumab course in RRMS patients with disease activity after three prior courses: analysis of CARE-MS I Published: 2018 in European Journal of Neurology 1Identifying disability level in multiple sclerosis patients in a US-based health plan claims database Published: Jan 2021 in Journal of Medical Economics DOI: 10.1080/13696998.2020.1857257

21. Efficacy of a Third Course of Alemtuzumab in Patients with Active Relapsing Remitting Multiple Sclerosis Who Experienced Disease Activity After the Initial Two Courses: Pooled Analysis of CARE-MS I and II Published: 2018 in Multiple Sclerosis Journal

22. 7-year outcomes in MS patients of African descent treated with alemtuzumab: follow-up of CARE-MS I and II (TOPAZ Study) Published: 2018 in Multiple Sclerosis Journal

23. Additional courses of alemtuzumab improved clinical and MRI outcomes in pooled CARE-MS I and II patients with disease activity after two courses: analysis of patients who received >= 3 courses Published: 2018 in Multiple Sclerosis Journal

24. Efficacy of Alemtuzumab Retreatment in Patients Who Experienced Disease Activity after the Initial Two Courses: Results from the CARE-MS II Extension Published: 2018 in Multiple Sclerosis Journal 0

25. Dextromethorphan/Quinidine in Migraine Prophylaxis: An Open-label Observational Clinical Study Published: 2018 in Clinical Neuropharmacology DOI: 10.1097/WNF.0000000000000272 0

26. Additional courses of alemtuzumab improved clinical and MRI outcomes in pooled CARE-MS I and II patients with disease activity after three courses: analysis of patients who received >= 4 courses Published: 2018 in Multiple Sclerosis Journal 0

27. Long-term efficacy and safety of Alemtuzumab in patients with RRMS: 12-year follow-up of the CAMMS223 study Published: 2019 in Multiple Sclerosis Journal 1 Effectiveness of alternative dose fingolimod for multiple sclerosis Published: Apr 2018 in Neurology Clinical Practice DOI: 10.1212/CPJ.0000000000000434 7

28. Long-Term Outcomes in Patients with Progressive Forms of Relapsing MS Treated with Teriflunomide: Real-World Evidence Published: Feb 2018 in Multiple Sclerosis Journal 0

29. Assessment of clinical disease activity and disability improvement by numberneeded-to-treat analyses in patients with relapsing multiple sclerosis treated with alemtuzumab or ocrelizumab Published: Feb 2018 in Multiple Sclerosis Journal 0

30. Efficacy of Alemtuzumab in Patients With Active Relapsing-Remitting Multiple Sclerosis Who Received Retreatment Due to Disease Activity After the Initial Two Courses: Results From the CARE-MS I Extension Published: 2018 in Neurology 0

31. Efficacy of Alemtuzumab in Patients With Active Relapsing-Remitting Multiple Sclerosis Who Received Retreatment Due to Disease Activity After the Initial Two Courses: Results From the CARE-MS II Extension Published: 2018 in Neurology 0

32. Long-Term Outcomes in Patients With Progressive Forms of Relapsing MS Treated With Teriflunomide: Real-World Evidence Published: 2018 in Neurology

33. Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study) Published: Dec 2019 in Neurology and Therapy DOI: 10.1007/S40120-019-00159-2 0

34. Berkovich R et al. Identifying disability level in multiple sclerosis patients in a US-based health plan claims database Published: Sep 2019 in Multiple Sclerosis Journal

35. Number Needed to Treat to Prevent Relapse and Disability Worsening Among Patients with Relapsing MS Treated with Teriflunomide or Cladribine Published: Apr 2019 in Neurology

36. 7-Year Outcomes in MS Patients of African Descent Treated With Alemtuzumab: Follow-up of CARE-MS I and II (TOPAZ study) Published: Apr 2019 in Neurology 0

37. Disability Level and Comorbidity Burden among Multiple Sclerosis (MS) Patients in the US Published: Apr 2019 in Neurology 0 PML Risk Perception in Patients Initiating Natalizumab for Multiple Sclerosis Published: 2019 in Neurology 0

38. Additional Courses of Alemtuzumab Improved Clinical and MRI Outcomes in Pooled CARE-MS I and II Patients With Disease Activity After Two Courses: Analysis of Patients Who Received >= 3 Courses Published: 2019 in Multiple Sclerosis Journal 0

39. Treatment With Additional Courses of Alemtuzumab Improves Clinical and MRI Outcomes in RRMS Patients With Disease Activity After Three Courses: Analysis of CARE-MS Patients Who Received >= 4 Courses Published: 2019 in Neurology 0

40. Use of other disease-modifying therapies after or between alemtuzumab treatments: pooled results from the CAMMS223, and CARE-MS I and II studies over 8 years Published: 2019 in European Journal of Neurology 0

41. Real-world experience in rrms and spms patients with higher disability and substantial lymphopenia switching from prior dmts to teriflunomide Published: Dec 2020 in Multiple Sclerosis Journal

42. Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study Published: Sep 2020 in CNS Drugs DOI: 10.1007/S40263-020-00749-X 1

43. Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223 Published: Jun 2020 in Journal of Neurology DOI: 10.1007/S00415-020-09983-1 1 Alemtuzumab Outcomes Over 9 Years in RRMS Patients With Highly Active Disease From CARE-MS I and II (TOPAZ) Published: May 2020 in European Journal of Neurology 0

44. Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CAREMS, extension, and TOPAZ studies Published: Dec 2020 in Multiple Sclerosis Journal DOI: 10.1177/1352458519888610 8

45. Experience of Using Adrenocorticotropic Hormone in the Treatment of Patients With Acute Neuromyelitis Optica Who Failed Systemic Steroids: A Case Series. R. Berkovich. Published: 2020 in Clinical Neuropharmacology DOI: 10.1097/WNF.0000000000000373 0 ersonal contribution: original idea, clinical observations and data collection, literature review and writing.

46. Improvement of Co-Morbid Psoriasis in Patients with MS Treated with Natalizumab. Berkovich R, Yakupova A, Eskenazi J, Carlson N, Steinman L. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 33589543 Personal contribution: original idea, clinical observations and data collection, literature review and writing.

47. Identifying disability level in multiple sclerosis patients in a U.S.-based health plan claims database. Berkovich R, Fox E, Okai A, Ding Y, Gorritz M, Bartolome L, Wade RL, Su W, Johnson KM, Russo P.J Med Econ. 2021 Jan-Dec;24(1):46-53. doi: 10.1080/13696998.2020.1857257.PMID: 33297816

48. Progressive Multifocal Leukoencephalopathy Risk Perception in Patients Considering Natalizumab for Multiple Sclerosis. Berkovich R, Eskenazi J, Yakupova A, Riddle EL.Int J MS Care. 2022 Jan-Feb;24(1):13-17. doi: 10.7224/1537-2073.2020-068. Epub 2021 Apr 8.PMID: 3526156 Personal contribution: original idea, clinical observations and data collection, literature review and writing.

49. Characterizing the ‘feel-good experience’ in multiple sclerosis patients treated with natalizumab or other therapies. John Foley, Regina Berkovich, Mark Gudesblatt et al. Neurogener Dis Manag. 2022 Oct 26, doi:10.2217/nmt-2022-0003. Personal contribution: original idea, clinical observations and data collection, literature review and writing.

50. Regina Berkovich et al. Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis. Mult Scler Relat Disord 2022 Dec 18;70:104472. Doi: 10.1016/jmsard.2022.104472 Personal contribution: original idea, clinical observations and data collection, literature review and writing.

51. Berkovich R, Negroski D, Wynn D, Sellers D, Bzdek KG, Lublin AL, Rawlings AM, Quach C, Wells DP, Dumlao M, Bora A, Ranno AE, Luo KL, Chavin J, Hua LH, Becker D. Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis. Mult Scler Relat Disord. 2023 Feb;70:104472. doi: 10.1016/j.msard.2022.104472. Epub 2022 Dec 18. PMID: 36566698.

52. Dolgorukova A, Protsenko E, Isaeva J, Gagloeva V, Verbitskaya E, Berkovich R, Sokolov AY. Meta-analysis of the effects of anti-migraine therapeutics in the rat trigeminovascular nociception model as a tool for design optimization. Eur J Neurosci. 2023 Jul;58(1):2339-2360. doi: 10.1111/ejn.16030. Epub 2023 May 14. PMID: 37143185.

53. Foley J, Berkovich R, Gudesblatt M, Luce E, Schneider B, de Moor C, Liao S, Lee L, Bodhinathan K, Avila R. Characterizing the 'feel-good experience' in multiple sclerosis patients treated with natalizumab or other therapies. Neurodegener Dis Manag. 2023 Feb;13(1):23-34. doi: 10.2217/nmt-2022-0003. Epub 2022 Oct 26. PMID: 36285716.

54. Sokolov AY, Mengal M, Berkovich R. Menthol dural application alters meningeal arteries tone and enhances excitability of trigeminocervical neurons in rats. Brain Res. 2023 Dec 20;1825:148725. doi: 10.1016/j.brainres.2023.148725. Epub ahead of print. PMID: 38128811.

55. Rousseau FS, Wang L, Sprague TN, Lategan TW, Berkovich RR. Comparative pharmacokinetics and bioavailability of monomethyl fumarate following a single oral dose of Bafiertam® (monomethyl fumarate) versus Vumerity® (diroximel fumarate). Mult Scler Relat Disord. 2023 Feb;70:104500. doi: 10.1016/j.msard.2023.104500. Epub 2023 Jan 3. PMID: 36645997.

REFEREED REVIEWS, CHAPTERS, AND EDITORIALS:

1. Berkovich RR. Acute Multiple Sclerosis Relapse. American Academy of Neurology. Continuum (Minneap Minn). 2016 Aug;22(3):799-814. Doi: 10.1212/CON.000000000000330

2. Berkovich R. Book chapter: Immunology and treatment of acute relapses in MS. Translational Neurology.

3. Berkovich R. Book Chapter: Immunology of MS in the book “Multiple Sclerosis for the Non-Neurologist”. Wolters Kluwer, 2019

REFEREED ON-LINE PUBLICATIONS:

1. Berkovich R, Kantor D. Reder AT, editor. Multiple sclerosis: treatment of its symptoms. MedLink Neurology. San Diego: MedLink Corporation. Available at www.medlink.com. Publication dates: Originally released September 11, 2002; last updated March 4, 2013; expires March 4, 2016 http://www.medlink.com/article/immunomodulatory_agents_in_ms_clinical_trials_and_therapy

2. Berkovich R, Kantor D. Reder AT, editor. Immunomodulatory agents in MS: clinical trials and therapy. MedLink Neurology. San Diego: MedLink Corporation. Available at www.medlink.com. Publication dates: Originally released November 12, 2002; last updated June 10, 2013; expires June 10, 2016 http://www.medlink.com/article/multiple_sclerosis_treatment_of_its_symptoms

NON-REFEREED JOURNAL ARTICLES, REVIEWS, OR OTHER COMMUNICATIONS:

1. Zimakova IE, Salikhova RR (aka Berkovich R), Tagirova TS, Karpov AM. The use of Mebicar for complex therapy of atherosclerosis. Kazan State Medical Academy Methodological Recommendations. 1:1-22, 1995.

2. Salikhova RR (aka Berkovich R). The impact of the tranquillizers Mebicar and Seduxen on the lipid metabolism and lipid peroxydation. The Thesis’s of the Conference of Young Scientists, Kazan State Medical Academy. 1:73–76, 1996.

3. Zimakova IE, Garaev RS, Salikhova RR (aka Berkovich R). Stress protective and hypolipidemic effects of Mebicar. The Thesises of the 2nd Russian National Congress “Human Being and Medicine”, Moscow, 2:295–296, 1995.

4. Dautova RK, Zimakova IE, Tagirova TS, Salikhova RR (aka Berkovich R). The potential use of Mebicar in correction of metabolism. Modern Problems of Psychiatry. 67-69, 1994.

5. Tagirova TS, Zimakova IE, Salikhova RR (aka Berkovich R). Hypolipidemic Effects of Mebicar. Modern Problems of Psychiatry. 124–125, 1994.

6. Tagirova TS, Zimakova IE, Salikhova RR (aka Berkovich R). Effects of Mebicar in correction of lipid metabolism in rats. The Thesis’s of the Republic Scientific Conference. 116–118,1994.

7. Salikhova RR (aka Berkovich R). The impact of anti anxiety medication Mebicar on the Malone Dialdehyde contents in tissues and blood lipid spectrum of rats. The Journal of the European College of Neuropsychopharmacology.10:69, 2000.

8. Berkovich R. Natalizumab reduces apathy in relapsing remitting multiple sclerosis patients. European Neuropsychopharmacology. 21:154-155, 2011.

9. Беркович РР. Воспоминания о Юрии Дмитриевиче. Академик РАМН Юрий Дмитриевич Игнатов. Издательство ПСПбГМУ им. акад. И. П. Павлова. Санкт-Петербург, 2015. [Berkovich R. Memories of Yuri Dmitrievich. Academician of Russian Academy of Medical Sciences Yuri Dmitrievich Ignatov. St.-Petersburg, 2015]

BOOKS, MONOGRAPHS, AND TEXT BOOKS:

Berkovich R. “See a Bigger Picture” for Children who have a parent with Multiple Sclerosis. Written and Illustrated by Regina Berkovich, MD, PhD, MS Specialist - sponsored by Teva Neuroscience, 38 pages, 100.000 copies, 2011.

SELECTED ABSTRACTS AND PLATFORM PRESENTATIONS:

Amezcua L, Berkovich R, Tsao-Wei D et al. IFN ß1a induced changes in myelin-specific T cell frequency may serve as a biomarker predicting clinical outcome. The Twelfth Annual Meeting of Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) June 2, 2007.

Berkovich R. Four cases of co-morbid multiple sclerosis and psoriasis: sustained remission of both conditions while on natalizumab. Poster presented at: 62nd Annual Meeting of the American Academy of Neurology; 2010 April 10-17; Toronto, Canada.

Berkovich R, Spann B. Apathy in multiple sclerosis and its association with depression, fatigue, and cognitive impairment. Poster presented at: 62nd Annual Meeting of the American Academy of Neurology; 2010 April 10-17; Toronto, Canada.

Amezcua L, Berkovich R, Burnett M, Aparicio J, Kachuck N. Expanded laboratory surveillance for PML in a large cohort of patients on natalizumab for multiple sclerosis. Poster presented at: 62nd Annual Meeting of the American Academy of Neurology; 2010 April 10-17; Toronto, Canada.

Lerner A, Berkovich R, Law M. DTI in multiple sclerosis patients with and without apathy. Poster presented at: 48th Annual Meeting of the American Society for Neuroradiology; 2010 May 15-20; Boston, MA.

Berkovich R, Gilmore W, Lund B. Monthly pulse adrenocorticotropin hormone versus methylprednisolone for multiple sclerosis treatment. International Journal of MS Care. 2010;12 (suppl 1):81.

Williamson E, Subhani D and Berkovich R. Case report: Progressive encephalopathy in Multiple Sclerosis patient responsive to plasma exchange. CMSC 2012 abstracts_Int J of MS Care pg 46-47

Berkovich R. Role of ACTH in MS. National MS Society Research Meeting. San Francisco, August 2011.

Berkovich R, Fernandez M, Subhani S. Monthly pulse adrenocorticotropic hormone (ACTH) or methylprednisolone therapy for long- term treatment of multiple sclerosis as an add-on therapy to beta-interferons: interim results from a pilot study. Multiple Sclerosis. ECTRIMS 2011; 17(suppl 1): S249-250. Amsterdam, Netherlands.

Berkovich R, Fernandez M, Subhani D. "Adrenocorticotropic hormone treatment of multiple sclerosis exacerbations" CMSC-ACTRIMS 2012; Abstract DX66. San Diego, CA.

Berkovich R, Togasaki D, Subhani D, Steinman L. Dynamics of the peripheral blood CD4 cell counts of JCV Ab positive patients at the different phases of natalizumab treatment. ECTRIMS October 12, 2012, Lyon, France.

Berkovich R, Amezcua L, Subhani D, Cen S. Pilot study of monthly pulse adrenocorticotropic hormone (ACTH) or methylprednisolone as an add-on therapy to beta-interferons for long-term treatment of multiple sclerosis. Presented at the American Academy of Neurology’s 65 th Annual Meeting. San Diego, CA. March 16 - 23, 2013. Neurology 2013; 80(19): e205-e206

Amezcua L, Axtell R, Cen S, Tauhid S; Neema M, Subhani D, Bakshi R, Steinman L & Berkovich R. Pilot Study of Monthly Pulse Adrenocorticotropic Hormone or Methylprednisolone as an Add-on Therapy to β-interferons for Long-term Treatment of Multiple Sclerosis. Presented at the 29th European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), October 2-5, 2013. (P1097). Multiple Sclerosis. October 2013; 19(11 suppl): 514-151. Copenhagen, Denmark.

Totolyan N, Berkovich R. Alemtuzumab safety data – presented at the Congress of the Russian Committee for Treatment and Research in Multiple Sclerosis (RUCTRIMS). September 2015. Yaroslavl. Russia.

Javed A, Berkovich R, Hendin B, Miller A, Tornatore C. Use of patient case scenarios to assess current practice patterns of MS relapse assessment and treatment among MS specialists in the United States. P671. ECTRIMS October 8, 115567, 2015. Barcelona, Spain

LaGanke C, Hughes B, Berkovich R, Cohen J, Giovannoni G, Kasten L, Margolin D, Havrdova E. ; on behalf of the CARE-MS II Investigators Durable Effect of Alemtuzumab on Disability Improvement in Patients With Relapsing-Remitting Multiple Sclerosis Who Relapsed on a Prior Therapy. P3.261. 67th Annual Meeting of the American Academy of Neurology (AAN) April 18–25, 2015. Washington, DC, USA

Giovannoni G, Berkovich R, Fernandez O,Fox E, Wiendl H, Margolin D, Kasten L, LaGanke C; on behalf of the CARE-MS II Investigators. Durable Improvement in Expanded Disability Status Scale Functional Systems Scores Over 4 Years With Alemtuzumab Despite a Majority of Patients Not Receiving Treatment Since Year 1. P1104. 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) October 7–10, 2015. Barcelona, Spain

Khan, O., Berkovich, R., Hendin, B., Javed, A., Miller, C., Tornatore, C. Current practice patterns of MS management among MS specialists in the United States: survey results of the MS relapse practice patterns project. ECTRIMS, October 2017, Paris, France

Berkovich, R., Aparicio, J., Tarlow, L., Palomeque, A., Amezcua, L. A non-randomized, open label, exploratory study of dalfampridine-extended release and sexual dysfunction in women with multiple sclerosis. ECTRIMS, October 2017, Paris, France

Javed, A., Berkovich, R., Hendin, B., Miller, A., Tornatore, C. Use of patient case scenarios to assess current practice patterns of MS relapse assessment and treatment among MS specialists in the United States. ECTRIMS, October 2017, Paris, France

AAN Platform Presentation (MS and CNS Inflammatory Disease, April 24, 2017)

006 A. Rovira (Vall d'Hebron University Hospital), A. Boster (Ohio State University), G. Comi (University Vita-Salute San Raffaele), R. Berkovich (University of Southern California, Keck School of Medicine), D. Pelletier (University of Southern California, Keck School of Medicine), S. Schippling (University Hospital), A. Traboulsee (University of British Columbia), C. LaGanke (North Central Neurology Associates, PC), D. Margolin (Sanofi Genzyme), S. Santra (Cytel), D. Arnold (NeuroRx Research), o. Investigators. Alemtuzumab Decreased MRI Disease Activity Through 6 Years in Patients With Highly Active RRMS and an Inadequate Response to Prior Therapy: CARE-MS II Extension Study .

AAN Platform Presentation (MS and CNS Inflammatory Disease, April 26, 2017)

I. Kister (NYU School of Medicine, NY), D. Kantor (Kantor Neurology), S. Khoury (Nehme and Therese Tohme MS Center), M. Rice (MS Center of Tidewater), E. Lathi (The MS Ctr/Dept of Neuro), A. Caminero Rodriguez (C/ Fuentes Claras #1), S. Pawate (Vanderbilt University Medical Center), M. Bradshaw, MD (Vanderbilt University Medical Center), K. Edwards (MS Center of Northeastern NY - Empire Neurology, P.C.), A. Cross (Washington University School of Medicine), B. Parks (Washington University School of Medicine), J. Lynch (CoxHealth), R. Archer (University of Arkansas for Medcial Sciences), W. Meador (The University of Alabama at Birmingham), R. Berkovich (Keck School of Medicine of USC), B. Yamout (American University of Beirut), M. Zeineddine (American University of Beirut), D. VanderKodde (Spectrum Health Medical Group), G. Von Geldern (University of Wisconsin Medical Center), L. Ge (NYU School of Medicine), S. Russell (BarnabasRWJ), T. Bacon (NYU School of Medicine, NY), E. Longbrake (Yale University)

007 Alternate dosing of fingolimod for Multiple Sclerosis. AAN 2017

R. Berkovich (Keck School of Medicine of USC). Effects of Alemtuzumab on Disability and Cognition in Patients with Secondary Progressive Multiple Sclerosis (SPMS). AAN 2017

E. Williamson (University of Pennsylvania Penn Neuroscience Center), H. Zhang

J. Aldridge, S. Baver, R. Berkovich (University of Southern California) Efficacy of Interferon ß-1a Subcutaneously Three Times Weekly According to Baseline EDSS/Duration, EDSS, and MSSS Subgroups: Post Hoc Analysis of PRISMS Data. AAN 2017

G. Comi (University Vita-Salute San Raffaele), R. Alroughani (Amiri Hospital), R. Berkovich (University of Southern California, Keck School of Medicine), et al. Number Needed to Treat Analyses to Assess Clinical Outcomes in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Alemtuzumab or Ocrelizumab. AAN 2017

Aaron Boster, MD , OhioHealth Neurological Physicians, Columbus, OH; Raed Alroughani, MD , Amiri Hospital; Sharq, Kuwait; Regina Berkovich, MD, PhD , University of Southern California, Keck School of Medicine, Los Angeles, CA; Giancarlo Comi, MD et al. Number Needed to Treat Analyses Comparing Outcomes in Patients with Relapsing-Remitting Multiple Sclerosis Treated with Alemtuzumab or Ocrelizumab. CMSC. May 25, 2017. B2 (New Orleans Convention Center).

Anthony Traboulsee, MD , University of British Columbia, Vancouver, BC, Canada; Michael Barnett, PhD, MD , University of Sydney, Sydney, NSW, Australia; Regina Berkovich, MD, PhD , University of Southern California, Keck School of Medicine, Los Angeles, CA; Aaron Boster, MD , OhioHealth Neurological Physicians, Columbus, OH; Giancarlo Comi, MD , University Vita-Salute San Raffaele, Milan, Italy; CARE-MS I and CAMMS03409 Investigators, n/a , MA. Durable Efficacy of Alemtuzumab on MRI Disease Activity over 6 Years in Treatment-Naive RRMS Patients with Highly Active Disease: Care-MS I Extension.

CMSC, May 25, 2017. B2 (New Orleans Convention Center).

Regina Berkovich, MD, PhD , MS Comprehensive Care Center and Research Group, University of Southern California, Los Angeles, CA; Hao Zhang, PhD , EMD Serono, Inc., Billerica, MA; Julie Aldridge, MS , EMD Serono, Inc., Billerica, MA; Scott Baver, PhD , EMD Serono, Inc., Rockland, MA; Eric Williamson, MD , University of Pennsylvania Penn Neuroscience Center, Philadelphia, PA; Mary Lee, NA , Caudex, New York, NY; Michele Springer, BA , Caudex, New York, NY. Post Hoc Analysis of PRISMS Study: Efficacy of Interferon beta-1a Subcutaneously Three Times Weekly According to Baseline EDSS/Duration, EDSS, and MSSS Subgroups. CMSC, May 25, 2017. B2 (New Orleans Convention Center).

Identifying disability level in multiple sclerosis patients in a U.S.-based health plan claims database. Scientific session. Platform presentation. ECTRIMS. Stockholm, Sweden. Berkovich R. Sep 13, 2019; 279554; 293

MEDIA AND TELEVISION APPEARANCES:

1. 2009, Interview for the Burbank Leader “Reaching for the sky” October 24, 2009

2. 2014, Interview by Olga Rukovets, Pregnancy Hormone found to Reduce Relapses in Women with MS. Neurology Today, June 19, 14(12), 8.

3. 2015, Interview by Jack Osborn for his program “You don’t know Jack”, USC

4. 2017, Interview by Martin Booe, Staying on Course. USC Health, A Publication of Keck Medicine of USC. Vol. 2017 Issue 1, 12-13.

5. 2019, National Radio podcasts. Series of Interviews on Secondary Progressive Multiple Sclerosis.

6. 2021. Introducing, Selma Blair. Documentary.